Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Lutathera
Lutathera
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors
Novartis eyes first-line use of Lutathera after trial win
Pharmaphorum
Mon, 09/25/23 - 11:41 am
Novartis
radioligands
clinical trials
neuroendocrine tumors
Lutathera
Novartis' surprise radiotherapy production halt nearing an end as FDA docs shed light on plant woes
Fierce Pharma
Thu, 06/2/22 - 10:20 am
Novartis
radiotherapy
FDA
Lutathera
Pluvicto
Novartis plots 2nd U.S. factory to meet demand for Lutathera and future cancer radiotherapies
Fierce Pharma
Wed, 07/1/20 - 11:17 am
Novartis
Lutathera
radiotherapy
drug manufacturing
ESMO: Eyeing Novartis and Pfizer, Chi-Med touts neuroendocrine cancer win
Fierce Pharma
Mon, 09/30/19 - 10:38 am
Chi-Med
surufatinib
Pfizer
Sutent
Novartis
Afinitor
Lutathera
neuroendocrine tumors. ESMO
As Novartis' other cancer launches struggle, Lutathera gets off to flying start
Fierce Pharma
Fri, 11/9/18 - 11:43 am
Novartis
Lutathera
drug launches
neuroendocrine tumors
FDA approves Novartis-acquired Lutathera for certain gut cancers
Biopharma Dive
Mon, 01/29/18 - 03:21 pm
Novartis
FDA
Lutathera
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Endpoints
Fri, 01/26/18 - 05:25 pm
Novartis
Lutathera
FDA
neuroendocrine tumors
Buyout buzz: Novartis has been kicking the tires at AAA as FDA reviews Lutathera — report
Endpoints
Thu, 09/28/17 - 11:08 am
Novartis
FDA
Lutathera
M&A
Advanced Accelerator Application